Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HMGB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HMGB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HMGB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HMGB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HMGB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HMGB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HMGB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HMGB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HMGB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HMGB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HMGB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HMGB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00506784 | Stomach | GC | regulation of epithelial cell proliferation | 39/1159 | 381/18723 | 1.42e-03 | 1.55e-02 | 39 |
GO:1902106 | Stomach | GC | negative regulation of leukocyte differentiation | 15/1159 | 102/18723 | 1.49e-03 | 1.62e-02 | 15 |
GO:00987606 | Stomach | GC | response to interleukin-7 | 5/1159 | 15/18723 | 1.60e-03 | 1.70e-02 | 5 |
GO:00987616 | Stomach | GC | cellular response to interleukin-7 | 5/1159 | 15/18723 | 1.60e-03 | 1.70e-02 | 5 |
GO:0045639 | Stomach | GC | positive regulation of myeloid cell differentiation | 15/1159 | 103/18723 | 1.65e-03 | 1.75e-02 | 15 |
GO:0032640 | Stomach | GC | tumor necrosis factor production | 22/1159 | 181/18723 | 1.88e-03 | 1.94e-02 | 22 |
GO:0032680 | Stomach | GC | regulation of tumor necrosis factor production | 22/1159 | 181/18723 | 1.88e-03 | 1.94e-02 | 22 |
GO:0042129 | Stomach | GC | regulation of T cell proliferation | 21/1159 | 171/18723 | 2.08e-03 | 2.09e-02 | 21 |
GO:00433885 | Stomach | GC | positive regulation of DNA binding | 10/1159 | 56/18723 | 2.08e-03 | 2.09e-02 | 10 |
GO:0001819 | Stomach | GC | positive regulation of cytokine production | 45/1159 | 467/18723 | 2.17e-03 | 2.16e-02 | 45 |
GO:1903707 | Stomach | GC | negative regulation of hemopoiesis | 15/1159 | 106/18723 | 2.21e-03 | 2.18e-02 | 15 |
GO:00071623 | Stomach | GC | negative regulation of cell adhesion | 32/1159 | 303/18723 | 2.24e-03 | 2.20e-02 | 32 |
GO:00060064 | Stomach | GC | glucose metabolic process | 23/1159 | 196/18723 | 2.39e-03 | 2.29e-02 | 23 |
GO:00510996 | Stomach | GC | positive regulation of binding | 21/1159 | 173/18723 | 2.40e-03 | 2.30e-02 | 21 |
GO:00432805 | Stomach | GC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 17/1159 | 129/18723 | 2.54e-03 | 2.39e-02 | 17 |
GO:0071219 | Stomach | GC | cellular response to molecule of bacterial origin | 25/1159 | 221/18723 | 2.62e-03 | 2.45e-02 | 25 |
GO:0071706 | Stomach | GC | tumor necrosis factor superfamily cytokine production | 22/1159 | 186/18723 | 2.66e-03 | 2.46e-02 | 22 |
GO:1903555 | Stomach | GC | regulation of tumor necrosis factor superfamily cytokine production | 22/1159 | 186/18723 | 2.66e-03 | 2.46e-02 | 22 |
GO:00506734 | Stomach | GC | epithelial cell proliferation | 42/1159 | 437/18723 | 3.13e-03 | 2.78e-02 | 42 |
GO:0032760 | Stomach | GC | positive regulation of tumor necrosis factor production | 14/1159 | 103/18723 | 4.42e-03 | 3.60e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMGB1 | SNV | Missense_Mutation | | c.120N>C | p.Glu40Asp | p.E40D | P09429 | protein_coding | deleterious(0.02) | benign(0.105) | TCGA-D8-A1XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
HMGB1 | SNV | Missense_Mutation | | c.131A>C | p.Lys44Thr | p.K44T | P09429 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.624A>T | p.Glu208Asp | p.E208D | P09429 | protein_coding | tolerated_low_confidence(0.26) | benign(0) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.443C>G | p.Ala148Gly | p.A148G | P09429 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
HMGB1 | SNV | Missense_Mutation | novel | c.377C>T | p.Ala126Val | p.A126V | P09429 | protein_coding | deleterious(0.03) | benign(0.221) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.168G>T | p.Glu56Asp | p.E56D | P09429 | protein_coding | deleterious(0.04) | benign(0.105) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
HMGB1 | SNV | Missense_Mutation | | c.253N>G | p.Thr85Ala | p.T85A | P09429 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.23N>G | p.Lys8Arg | p.K8R | P09429 | protein_coding | deleterious(0.02) | benign(0.358) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.25N>T | p.Pro9Ser | p.P9S | P09429 | protein_coding | deleterious(0.04) | possibly_damaging(0.573) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.488G>A | p.Arg163Gln | p.R163Q | P09429 | protein_coding | tolerated(0.16) | benign(0.193) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | PREDNISOLONE | PREDNISOLONE | 18447956 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AUTOLOGOUS DENDRITIC CELLS | | 16997859 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | ADJUVANT | | 15161015 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | SALINE | SODIUM CHLORIDE | 17334244 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | DISTAMYCIN | | 9161031 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | GP100 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | CHLORAMPHENICOL | CHLORAMPHENICOL | 9931456 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | EGCG | EPIGALOCATECHIN GALLATE | 17987129 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | MART1 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AMPICILLIN | AMPICILLIN | 9931456 |